பிரிவு ஆஃப் சிறுநீரக புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பிரிவு ஆஃப் சிறுநீரக புற்றுநோயியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பிரிவு ஆஃப் சிறுநீரக புற்றுநோயியல் Today - Breaking & Trending Today

American Urological Association Names Next Science and Quality Chair


American Urological Association Names Next Science and Quality Chair
News provided by
Share this article
Share this article
BALTIMORE, April 15, 2021 /PRNewswire/ Today, the American Urological Association (AUA) announced its Board of Directors has approved Matthew Nielsen, MD, MS, FACS, as the next chair of the AUA Science and Quality (S&Q) Council. Dr. Nielsen will assume the role of chair-elect on June 1, 2021 and begin his four-year term as chair on June 1, 2022.
Matthew Nielsen, MD, MS, FACS, the next chair of the AUA Science and Quality (S&Q) Council.
As chair, Dr. Nielsen will lead the AUA S&Q Council, providing strategic oversight to shape and execute on the broad science, quality and data agenda of the AUA to include the creation, dissemination and implementation of clinical guidelines and white papers; maintenance of the AUA Quality (AQUA) Registry; development and implementation of physician performance measures; advancement of patient saf ....

Johns Hopkins University , United States , Teri Arnold , Scott Swanson , Raju Thomas , Johns Hopkins , Patient Safety Committee , Urology Care Foundation , American Urological Association , Leadership Program , Institute For Healthcare Quality Improvement , Centers For Medicare , Performance Measurement Committee , Lineberger Comprehensive Cancer Center , Medicaid Service Technical Expert Panel , Physician Consortium For Performance Improvement , Gillings School Of Global Public Health , Multidisciplinary Genitourinary Oncology Group , Health Policy Management , University Of North Carolina Chapel Hill , Johns Hopkins University School Of Medicine , Division Of Urologic Oncology , Quality Measure Development Plan , Department Of Urology , Corporate Communications , Quality Search Committee ,

SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)


SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)
(UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
This debate follows the publication of the HERO trial,

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal of Medicine in June 2020 and of which Dr. Shore is the lead author. This was a randomized controlled comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide. 120mg relugolix was given by mouth daily and leuprolide was given every 3 months as depot injections. The primary end point was “sustained castration”, meaning a testosterone level ....

United States , Fox Chase Cancer Center , Marshall Strother , Ashley Ross , Ashley Evan Ross , Society Of Urologic Oncology Annual Meeting , Carolina Urologic Research Center , Division Of Urologic Oncology , Meeting Of The Society Urologic Oncology , United States Federal Drug Administration , Northwestern Medical Group , Health Drug , Feinberg School Of Medicine , Society For Urologic Oncology , Urologic Oncology , Neal Shore , Men With Advanced Prostate Cancer , New England Journal , Medical Director , Carolina Urologic Research , Associate Professor , Feinberg School , Northwestern Medical , Urologic Oncology Fellow , Urologic Oncology Annual Meeting , Treatment Patterns ,

SUO 2020: Optimizing Management of High Risk Non-Muscle-Invasive Bladder Cancer – Case Based Discussion


SUO 2020: Optimizing Management of High Risk Non-Muscle-Invasive Bladder Cancer – Case Based Discussion
(UroToday.com) The plenary session of the last day of the 2020 Annual Meeting of the Society of Urologic Oncology (SUO) began with a panel discussion stepping through the case of a patient with non-muscle invasive bladder cancer.
Dr. Sima Porten, the moderator, introduced the case: a 60-year-old otherwise healthy male with high-volume high-grade Ta urothelial carcinoma of the bladder diagnosed on an initial transurethral resection (TUR) with no muscle in the initial specimen.
The panel first addressed the question of perioperative chemotherapy for this patient. There was immediate resounding consensus that, based on the results of SWOG S0337 ....

University Of Washington Medical Center , United States , Fox Chase Cancer Center , University Of Missouri , Sumeet Bhanvadia , Sarah Psutka , Marshall Strother , Sima Porten , Sarahp Psutka , Sumeet Kaur Bhanvadia , Janet Baack Kukreja , Katies Murray , Janet Kukreja , Urological Oncology At Ellis Fischel Cancer Center , Society Of Urologic Oncology Annual Meeting , Missouri University Of , University Of Southern California , Professor For The Department Of Urology , Meeting Of The Society Urologic Oncology , Urology Division , United States Federal Drug Administration , University Of California San Francisco , Society For Urologic Oncology , University Of Colorado Denver , Keck School Of Medicine , Division Of Urologic Oncology ,